RecruitingNCT06893861

Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial Cancer

Sponsor

National Cancer Institute, Naples

Enrollment

3,100 participants

Start Date

Jul 6, 2023

Study Type

OBSERVATIONAL

Conditions

Endometrial Carcinoma (EC)

Summary

The study involves the use of reagents or materials for diagnostic assessments that are not commercially available, specifically a metabolomic signature for screening endometrial carcinoma and/or other types of cancers, and follows a case-control design. This study aims to achieve several objectives that contribute to evaluating the diagnostic potential of a specific "metabolomic signature" to be used for screening endometrial carcinoma. Specifically, the study seeks to assess the signature's discriminative ability in differentiating between benign endometrial neoplasms and neoplasms of different histological origins.

Eligibility

Sex: FEMALEMin Age: 50 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a metabolomics blood test — a test that measures hundreds of chemical compounds in the blood — can reliably detect endometrial cancer (cancer of the uterine lining) in postmenopausal women, with the goal of developing a better screening tool. **You may be eligible if...** - You are a woman aged 50–80 - You are postmenopausal - You are willing to participate and sign the consent form **You may NOT be eligible if...** - You have already had a hysterectomy (removal of the uterus) - You are currently taking hormone replacement therapy - You are currently on immunosuppressive therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMetabolomic profiling

Blood samples will be collected from these subjects, and following metabolomic profiling, the data will provide the foundation for training machine learning models capable of recognizing the metabolomic profiles of subjects with endometrial carcinoma and differentiating them from subjects with other conditions.

Locations(1)

Istituto Nazionale Tumori | "Fondazione Pascale"

Naples, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06893861

Related Trials

Study of GV20-0251 in Participants With Solid Tumor Malignancies

NCT070705183 locations

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT0566943013 locations